Implementation of Improved Method on Embedded Surveillance System with Reduced Power Usage

In this project design and implement a home embedded surveillance system with ultra-low alert power. Traditional surveillance systems suffer from an unnecessary waste of power and the shortcomings of memory conditions in the absence of invasion. In this design we pressure sensors as the alert group in windows and doors where an intruder must pass through. These low-power alert sensors wake up the MCU (Micro Controller Unit) which has power management for the ultrasonic sensors and PIR sensors indoors. This state transition method saves a large number of sensors required for the alert power. We also use the Majority Voting Mechanism (MVM) to manage the sensor groups to enhance the probability of multiple sensors sensing. After the MCU sends the sensor signals to the embedded system, the program starts the Web camera. Our sensing experiment shows that we reduce the system’s power consumption Keywords: Embedded Surveillance System, PIR Sensor, Ultrasonic Sensor, Low-PowerStat

Formulation and in Vitro Evaluation of Zidovudine Microspheres

The present study was to formulate and evaluate microencapsulated controlled release preparations of Zidovudine using ethyl cellulose as the retardant material with high entrapment efficiency and extended release. Ethylcellulose is a natural, biodegradable polymer and the method adopted for preparing microsphere was water-in-oil-in-oil (w/o/o) double emulsion solvent diffusion technique. Novel drug delivery system is finding more attention in pharmaceutical industries due to its various advantages. In the line sustained/controlled release formulations are more focused for improving the drug bioavailability with less dosing frequency. Zidovudine is one such compound having a poor bioavailability with high dosing frequency. The present investigation is focused to develop a suitable sustained release formulation for achieving better bioavailability and reduce dosing frequency. Zidovudine was formulated as microspheres using ethylcellulose. Compatibility studies were carried out using FTIR. The results suggest no evidence of any interaction. Different batches containing various concentrations of drug, polymer with varying volume of dispersion medium was prepared by double emulsion solvent diffusion technique. The in vitro release suggest that low volume of dispersion medium and low polymer ratio 64.05% of release at the end of 24 hrs with 65.12 % entrapment. It is evident that zidovudine loaded ethylcellulose microspheres showed better sustained release profile which is up to 24 hrs. The prepared formulation can be further evaluated to achieve a better bioavailability. IN VIVO studies can be carried out to optimize the Zidovudine microspheres using ethyl cellulose. The pharmacokinetic behavior of the formulated microspheres can be studies for optimization of the formulation

Pharmacological Evaluation of Canthium Coromandelicum (Burm.F) Alston in Experimental Animal Models

The present study Canthium coromandelicum is used traditionally for the treatment of diseases like HIV, diseases produced by micro organism , Diabetics, etc and is known as reputed drug of ayurveda. Our aim is to prepare the methanolic and aqueous extract of the leaves Canthium coromandelicum and to perform biological screening to elucidate the therapeutic potential of the plant considering their traditional usage, the following objectives are: Qualitative phyto chemical evaluations of Canthium coromandelicum, Hepatoprotective model and Diuretic model. CONCLUSION: HEPATOPROTECTIVE ACTIVITY : The hepatoprotective effect of aqueous and methanolic extract of Canthium coromandelicum leaves was confirmed by the following measures: The isolated livers from the toxicant (paracetamol) treated animals exhibited increase in wet liver weight. Indeed, extract treated animals exhibited decrease in the values of above physical parameters as an indication of hepatoprotection. Serum marker enzymes such as SGPT, SGOT and total bilirubin, showed marked increase. The same is observed in liver diseases in clinical practice and hence are having diagnostic importance in the assessment of liver function. In the present study, the methanolic and aqueous extract of Canthium coromandelicum leaves significantly reduced the elevated levels of above mentioned serum marker enzymes. Hence, at this point it is concluded that the methanolic and aqueous extract of Canthium coromandelicum leaves possesss hepatoprotective activity. In support to this study, histopathological results also show significant activity of the plant. In toxicant treated animals there will be severe disturbances in the cytoarchitecture of the liver. The same is observed in case of humans who are suffering from major liver disorders. But in the methanolic and aqueous extract of Canthium coromandelicum leaves treated group animals exhibited minimal hepatic derangements and intact cytoarchitecture of the liver was maintained. In addition to this there is regeneration of hepatocytes also observed, which indicating hepatoprotective activity. Finally based on improvement in serum marker enzyme levels, physical parameters, functional parameters and histopathological studies, it is concluded that the methanolic and aqueous extract of Canthium coromandelicum leaves possesses hepatoprotective activity and thus supports the traditional application of the same under the light of modern science. DIURETIC ACTIVITY : The diuretic effect of aqueous and methanolic extract of Canthium coromandelicum leaves was confirmed by the following measures: The urine levels and electrolyte levels such as sodium and potassium levels from the frusemide treated animals exhibited increased in above levels. Indeed, the aqueous and methanolic extract of Canthium coromandelicum leaves extract treated animals exhibited the significantly same in urine levels and electrolyte levels. Hence, at this point it is concluded that the aqueous and methanolic extract of Canthium coromandelicum leaves possesss diuretic activity

1-(6,8-Dibromo-2-methyl­quinolin-3-yl)ethanone

Two independent mol­ecules,1 and 2, with similar conformations comprise the asymmetric unit in the title compound, C12H9Br2NO. The major difference between the mol­ecules relates to the relative orientation of the ketone–methyl groups [the C—C—C—C torsion angles are −1.7 (6) and −16.8 (6)° for mol­ecules 1 and 2, respectively]; in each case, the ketone O atom is directed towards the ring-bound methyl group. The crystal packing comprises layers of mol­ecules, sustained by C—H⋯O and π–π {ring centroid(C6) of molecule 2 with NC5 of molecule 1 [3.584 (3) Å] and NC5 of molecule 2 [3.615 (3) Å]} interactions. C—H⋯Br contacts also occur

3-(4-Meth­oxy­phen­yl)-1-phenyl-1H-pyrazole-4-carbaldehyde

Four independent mol­ecules comprise the asymmetric unit of the title compound, C17H14N2O2. The central pyrazoline ring is flanked by an N-bound benzene ring and a C-bound meth­oxy-substituted benzene ring. The greatest difference between the independent mol­ecules is found in the relative orientations of the benzene rings with the range of dihedral angles being 23.59 (6)–42.55 (6)°. In the crystal, extensive C—H⋯O inter­actions link mol­ecules into layers parallel to (02) and these are linked by C—H⋯π contacts

N,N′-Bis[(E)-(5-chloro-2-thienyl)methyl­idene]ethane-1,2-diamine

The full mol­ecule of the title compound, C12H10Cl2N2S2, is generated by the application of a centre of inversion. The thio­phene and imine residues are co-planar [the N—C—C—S torsion angle is −2.5 (4)°] and the conformation about the imine bond [1.268 (4) Å] is E. Supra­molecular arrays are formed in the bc plane via C—Cl⋯π inter­actions and these stack along the a axis

3-(4-Bromo­phen­yl)-1-phenyl-1H-pyrazole-4-carbaldehyde

In the title compound, C16H11BrN2O, the phenyl and chloro­benzene rings are twisted out of the mean plane of the pyrazole ring, forming dihedral angles of 13.70 (10) and 36.48 (10)°, respectively. The carbaldehyde group is also twisted out of the pyrazole plane [the C—C—C—O torsion angle is 7.9 (3)°]. A helical supra­molecular chain along the b axis and mediated by C—H⋯O inter­actions is the most prominent feature of the crystal packing

[meso-5,10,15,20-Tetra­kis(5-bromo­thio­phen-2-yl)porphyrinato-κ4 N,N′,N′′,N′′′]nickel(II)

The NiII atom in the title porphyrin complex, [Ni(C36H16Br4N4S4)], is in a square-planar geometry defined by four pyrrole N atoms. There is considerable buckling in the porphyrin ring with the dihedral angles between the N4 donor set and the pyrrole rings being in the range 17.0 (3)–18.8 (3)°. Each of the six-membered chelate rings is twisted about an Ni—N bond and the dihedral angles between diagonally opposite chelate rings are 13.08 (15) and 13.45 (11)°; each pair of rings is orientated in opposite directions. The bromo­thienyl rings are twisted out of the plane of the central N4 core with dihedral angles in the range 51.7 (2)–74.65 (19)°. Supra­molecular chains along [001] are formed through C—H⋯Br inter­actions in the crystal packing. Three of the four bromo­thienyl units are disordered over two coplanar positions of opposite orientation with the major components being in 0.691 (3), 0.738 (3) and 0.929 (9) fractions

N,N′-Bis[(E)-(3-methyl-2-thienyl)methyl­idene]ethane-1,2-diamine

Two independent half-mol­ecules, each being completed by inversion symmetry, comprise the asymmetric unit of the title compound, C14H16N2S2. The major difference between the mol­ecules is found in the central C—C bond [the C—N—C—C torsion angles are 114.66 (18) and 128.94 (18)° in the two mol­ecules]. The thio­phene and imine groups are almost co-planar in each case [S—C—C—N torsion angles = −6.9 (2) and −3.6 (2)°]. In the crystal, the mol­ecules aggregate into supra­molecular chains via C—H⋯π inter­actions